Bimagrumab
As of the edition of 20 October 2026, Bimagrumab is an antibody: stopped in 2025; acts on ACVR2B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Antibody
- Registered trials
- 17, 2 stopped early
- Disease areas
- Nervous system; Nutrition and metabolism; Bones, joints and muscles; Hormones; Lungs and airways; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ACVR2B | Activin receptor type-2B | Q13705 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 13 | 9 | 2 | 2 |
| Phase 3 | 3 | 3 | 0 | 0 |
| All trials | 17 |